Rezultati pretrage - Srikumar Sahasranaman

  • Prikaz rezultata 1 – 5 od 5
Detaljiziraj rezultate
  1. 1
    Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy

    Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy od Lucy Lee, Manish Gupta, Srikumar Sahasranaman

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

    Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development od Anand Rotte, Srikumar Sahasranaman, Nageshwar Budha

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  3. 3
    A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

    A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia od Thomas J. Kipps, Herbert Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Iryna Dyagil, Sreeni Yalamanchili, Akiko Chai, Srikumar Sahasranaman, Elizabeth A. Punnoose, Deborah Hurst, Halyna Pylypenko

    Izdano 2015
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

    Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact od Yu Tian, Chi‐Yuan Wu, Srikumar Sahasranaman, Xianbin Tian, Ying Fei Li, Zhiyu Tang, Yanfei Yang, Ya Wan, Quting Zhang, Patrick Schnell, Ariadna Mendoza‐Naranjo, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha

    Izdano 2025
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors od Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel‐Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine Murray, Jennifer L. Schutzman, Jennifer Lauchle, Jean‐Charles Soria, Patricia LoRusso

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: